Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
- Ian D. Pavord1,
- Roland Buhl2,
- Monica Kraft3,
- Charlene M. Prazma4⇑,
- Robert G. Price5,
- Peter H. Howarth6 and
- Steven W. Yancey7
- 1Respiratory Medicine Unit and Oxford Respiratory National Institute for Health Research Biomedical Research Centre, Nuffield Department of Medicine, Oxford, UK
- 2Pulmonary Department, Johannes Gutenberg University of Mainz, Mainz, Germany
- 3Department of Medicine, University of Arizona, Tucson, AZ, USA
- 4Global Respiratory Franchise, Research Triangle Park, NC, USA
- 5Biostatistics, Hertfordshire, UK
- 6Respiratory Medical Franchise, Brentford, UK
- 7Respiratory Therapeutic Area, Research Triangle Park, NC, USA
- Charlene Prazma, Research Triangle Park, 5 Moore Drive, 13398, North Carolina, USA. E-mail: charlene.m.prazma{at}gsk.com
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: Ian Pavord reports support for the present manuscript received from GlaxoSmithKline: This study was funded by GSK; Medical writing support was provided by Fishawack Indicia Ltd and was funded by GSK. Grants or contracts received from Chiesi, outside the submitted work. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, GSK, Genentech, Novartis, Merck, Circassia and Knopp, outside the submitted work. Patents planned, issued or pending Leicester Cough Questionnaire: Co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer, and Insmed.
Conflict of interest: Roland Buhl reports support for the present manuscript received from GlaxoSmithKline: This study was funded by GSK; Medical writing support was provided by Fishawack Indicia Ltd and was funded by GSK. Grants or contracts received from Boehringer Ingelheim, GSK, Novartis and Roche, outside the submitted work. Consulting fees received from Boehringer Ingelheim, GSK, Novartis, Roche, AstraZeneca, Chiesi, Cipla, Sanofi and Teva, outside the submitted work.
Conflict of interest: Monica Kraft reports support for the present manuscript received from GlaxoSmithKline: This study was funded by GSK; Medical writing support was provided by Fishawack Indicia Ltd and was funded by GSK. Grants or contracts received from National Institutes of Health, American Lung Association, Chiesi, Sanofi and AstraZeneca, outside the submitted work. Participation on a Data Advisory Board for AstraZeneca and Sanofi/Regeneron. Other financial or non-financial interests; Chief Medical Officer for RaeSedo LLC.
Conflict of interest: Charlene Prazma reports support for the present manuscript received from GlaxoSmithKline: This study was funded by GSK; Medical writing support was provided by Fishawack Indicia Ltd and was funded by GSK. The author also reports owning stocks/shares in GlaxoSmithKline, as well as being a current employee of GlaxoSmithKline.
Conflict of interest: Robert Price reports support for the present manuscript received from GlaxoSmithKline: This study was funded by GSK; Medical writing support was provided by Fishawack Indicia Ltd and was funded by GSK. The author also reports owning stocks/shares in GlaxoSmithKline, as well as being a current employee of GlaxoSmithKline.
Conflict of interest: Peter Howarth reports support for the present manuscript received from GlaxoSmithKline: This study was funded by GSK; Medical writing support was provided by Fishawack Indicia Ltd and was funded by GSK. The author also reports owning stocks/shares in GlaxoSmithKline, as well as being a current employee of GlaxoSmithKline.
Conflict of interest: Steven Yancey reports support for the present manuscript received from GlaxoSmithKline: This study was funded by GSK; Medical writing support was provided by Fishawack Indicia Ltd and was funded by GSK. The author also reports owning stocks/shares in GlaxoSmithKline, as well as being a current employee of GlaxoSmithKline.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received September 17, 2021.
- Accepted December 5, 2021.
- Copyright ©The authors 2021
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org